Try a different challenge and make it count!
Are you carrying out work on behalf of charities?Would you like to do more in this area?If the answer is yes, tell the industry by entering the new, Charity Challenge today.
25th May 2018
Latest news
Enter now and take the next step in your career
The PharmaTimes Marketer of the Year Awards will return to London in November, alongside Communications Team of the Year and the all-new Sales Awards. Get involved with the 25th anniversary celebrations as this unique competition continues to raise standards, drive innovation and put patient outcomes at the centre of healthcare marketing.
25th May 2018
Have you entered the PharmaTimes Sales Awards yet?
If not, you should. Now!Dr Jim Golby PhD FCIPD, co-chair of the competition’s executive steering group (ESG) says: "I strongly believe that the newly imagined 2018 Pharma Sales Awards will provide a superb methodology for identifying and recognising the very best sales professionals in our Industry today.”
25th May 2018
Genmab/Novatis’ Arzerra fails to hit NHL targets
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin's lymphoma.
25th May 2018
US clears first enzyme therapy for PKU
Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.
25th May 2018
Imbruvica/Gazyva combo improves PFS in CLL patients
A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage clinical trial.
25th May 2018
NICE issues decision on Mylotarg, Besponsa for leukaemia
The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).
25th May 2018
EU nod for Sandoz’ Remicade biosimilar Zessly
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck & Co’s Remicade
24th May 2018
CQC finds half of A&E services sub-standard over winter
The Care Quality Commission has published a report concluding that some patients visiting A&E departments over the winter period received care that was "wholly unsatisfactory".
24th May 2018
NICE rejects Chiesi’s Lamzede
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
24th May 2018
Tax rises needed to boost health and social care funding
Tax rises will likely be needed to keep the quality of health and social care as it is now while the system contends with the growing demands of an ageing demographic, concludes a report by The Institute for Fiscal Studies and the Health Foundation.
24th May 2018
FDA clears Amgen’s Prolia for glucocorticoid osteoporosis
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
23rd May 2018
Clinigen, Mitsubishi link for early access programme
Clinigen says it has partnered with Mitsubishi Tanabe Pharma to initiate a Managed Access Program in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (ALS).
23rd May 2018
UK streams £30m into global fight against AMR
The UK government has announced that it will stream £30 million into global efforts to fight antimicrobial resistance (AMR).
23rd May 2018
EU approves Repatha for reduction of CV risk
The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).
23rd May 2018
